Last reviewed · How we verify
NCT04633616
Tailored Patient-Provider Communication (TPPC): Evaluating the Impact of TPPC in Dermatology Patients
NA trial testing Tailored Patient-Provider Communication in Psoriasis in 134 participants. Completed in 19 January 2022.
19 October 2021
Quick facts
| Lead sponsor | University of Southern California |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | other |
| Enrollment | 134 |
| Start date | 16 November 2020 |
| Primary completion | 19 October 2021 |
| Estimated completion | 19 January 2022 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Tailored Patient-Provider Communication
- Non-Tailored Patient-Provider Communication
Conditions studied
- Psoriasis — all drugs for Psoriasis →
- Atopic Dermatitis — all drugs for Atopic Dermatitis →
- Acne — all drugs for Acne →
Sponsor
University of Southern California
Who can join
18 and older, any sex, with Psoriasis or Atopic Dermatitis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The impact of tailored patient-provider communication to improve clinical trial recruitment, patient knowledge, and patient engagement will be studied. Tailored patient-provider communication refers to the individualization of patient-provider communication using patients' preferred methods of communication. This involves the utilization of social messaging such as e-mail or text and/or social media platforms. These communication methods purport to and meet individual patient needs whilst ensuring that information is received and in a format that is familiar to each patient. The primary outcomes of the proposed research is to evaluate the impact of tailored patient-provider communication on patient response rates (speed and number), clinical trial recruitment rates, patient knowledge, and patient engagement.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Educational and psychological interventions for managing atopic dermatitis (eczema).
Singleton H, Hodder A, Almilaji O, Ersser SJ, et al · · 2024 · cited 14× · PMID 39132734 · DOI 10.1002/14651858.cd014932.pub2
Verify or expand the search:
- PubMed search for NCT04633616
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Psoriasis
Currently open trials in the same condition.
- NCT07471048 — A Study to Evaluate the Impact of a Magnolia Officinalis Dietary Supplement on Immune Biomarkers in Subjects With Psoria · NA · recruiting
- NCT07449234 — A Study of Guselkumab After Switching From Ustekinumab in Participants With Moderate to Severe Psoriasis · recruiting
- NCT07234838 — Effect of Anti-Psoriatic Biologics on Risk of Anogenital Warts (CONDYPSO) · recruiting
- NCT07194200 — Safety and Efficacy of Lactobacillus Plantarum for Psoriasis: A Randomized Double-Blind Placebo-Controlled Trial · Phase 2 · recruiting
- NCT07250997 — PALLAS Laser for Skin Diseases · NA · recruiting
Other University of Southern California trials
Trials by the same sponsor.
- NCT07288463 — Hearing Loss and Genetic Risks for Alzheimer's Disease and Related Dementia · NA · not yet recruiting
- NCT05914233 — Non-invasive Ultrasound Retinal Stimulation for Vision Restoration · NA · not yet recruiting
- NCT06163664 — Role of ChatGPT in Vestibular Schwannoma Management · NA · withdrawn
- NCT07332312 — A Culturally Informed Patient Navigation Program (CFPN) to Reduce Delays Between Diagnosis and Treatment in American Ind · NA · not yet recruiting
- NCT07290478 — Encouraging Older Adults and Adults With Serious Illness to Designate a Health Care Proxy · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04633616 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Southern California
- Last refreshed: 15 December 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04633616.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing